{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:28:33Z","timestamp":1792214913704,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T00:00:00Z","timestamp":1739664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.esmoop.2025.104506","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T14:35:22Z","timestamp":1742308522000},"page":"104506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8775-503X","authenticated-orcid":false,"given":"S.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Climent Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.S.","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gurney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.P.","family":"Petrylak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"di Pietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Manitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Tyroller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2025.104506_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2025.104506_bib2","article-title":"A\u00a0review of the etiology and epidemiology of bladder cancer: all you need to know","volume":"14","author":"Halaseh","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104506_bib5","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104506_bib7","article-title":"Treatment patterns, indicators of receiving systemic treatment, and clinical outcomes in metastatic urothelial carcinoma: a retrospective analysis of real-world data in Germany","volume":"41","author":"Niegisch","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.104506_bib8","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2217\/fon-2023-0298","article-title":"Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis","volume":"20","author":"Kearney","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.esmoop.2025.104506_bib9","article-title":"Age and other criteria influencing nontreatment of patients (pts) with locally advanced or metastatic urothelial carcinoma (la\/mUC): results of a physician survey in 5 European countries (Eu5)","volume":"42","author":"Gupta","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.104506_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40266-018-0540-8","article-title":"Treatment of urothelial cancer in elderly patients: focus on immune checkpoint inhibitors","volume":"35","author":"Jodon","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.esmoop.2025.104506_bib11","first-page":"939","article-title":"Bladder cancer in the elderly patient: challenges and solutions","volume":"10","author":"Guancial","year":"2015","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.esmoop.2025.104506_bib12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.104506_bib13","series-title":"NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer v5.2024","year":"2024"},{"key":"10.1016\/j.esmoop.2025.104506_bib14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.esmoop.2025.104506_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.104506_bib16","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.104506_bib17","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2025.104506_bib18","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/cncr.31293","article-title":"Safety profile of avelumab in patients with advanced solid tumors: a pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials","volume":"124","author":"Kelly","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2025.104506_bib19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2022.04.016","article-title":"Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma","volume":"83","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.esmoop.2025.104506_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4515","article-title":"Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.104506_bib21","article-title":"Platinum eligibility criteria for patients with metastatic urothelial carcinoma (mUC): results of a physician survey in 5 European countries","volume":"42","author":"Gupta","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.104506_bib22","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4516","article-title":"Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial","volume":"41","author":"Bellmunt","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.104506_bib23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/00031305.1995.10476135","article-title":"Comparing treatments using quality-adjusted survival: the Q-TWiST method","volume":"49","author":"Gelber","year":"1995","journal-title":"Am Stat"},{"key":"10.1016\/j.esmoop.2025.104506_bib24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/pon.3595","article-title":"Quality-adjusted time without symptoms or toxicity (Q-TWiST): patient-reported outcome or mathematical model? A systematic review in cancer","volume":"24","author":"Tate","year":"2015","journal-title":"Psychooncology"},{"key":"10.1016\/j.esmoop.2025.104506_bib25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11136-005-1579-7","article-title":"Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data","volume":"15","author":"Revicki","year":"2006","journal-title":"Qual Life Res"},{"issue":"7463","key":"10.1016\/j.esmoop.2025.104506_bib26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2025.104506_bib27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.euo.2020.02.009","article-title":"Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer (KEYNOTE-052): outcomes in older patients by age and performance status","volume":"3","author":"Grivas","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.esmoop.2025.104506_bib28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2025.104506_bib29","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2025.104506_bib30","first-page":"S2588","article-title":"The overall survival benefit in EV-302: is enfortumab vedotin plus pembrolizumab the new frontline standard of care for metastatic urothelial carcinoma?","volume":"13","author":"Benjamin","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.esmoop.2025.104506_bib31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.euf.2024.03.005","article-title":"Front-line platinum continues to have a role in advanced bladder cancer","volume":"10","author":"Vogl","year":"2024","journal-title":"Eur Urol Focus"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925003758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925003758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:44:19Z","timestamp":1762598659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925003758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2059702925003758"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104506","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104506"}}